Nkarta, Inc. is preparing to release results from the NTRUST-1/2 Trials related to Myositis and Scleroderma at the ACR Conference, they were awarded a Safety Presentation as well on the efficacy and 0 side-effect therapies they have been dosing patients. CEO Paul Hastings on Stifel's investor forum questioned multiple aspects of their progress to date and both Hastings and President reinforced their findings and excitement to release not only results but durability of the drug. Their stock is cu
CryptoAlerta — análise de criptomoedas e mercado em tempo real